WuXi Biologics (Cayman) Inc. (2269.HK)
HKD 17.08
(-1.27%)
HKD 17.08
(-1.27%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 3.94 Billion CNY | -36.15% |
| 2022 | 6.15 Billion CNY | 59.69% |
| 2021 | 3.85 Billion CNY | 119.38% |
| 2020 | 1.75 Billion CNY | 58.41% |
| 2019 | 1.1 Billion CNY | 26.63% |
| 2018 | 876.43 Million CNY | 151.38% |
| 2017 | 348.64 Million CNY | 72.99% |
| 2016 | 201.53 Million CNY | 223.87% |
| 2015 | 62.22 Million CNY | 17.82% |
| 2014 | 52.81 Million CNY | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | 909.83 Million CNY | 0.0% |
| 2024 Q1 | 909.83 Million CNY | 10.55% |
| 2023 Q1 | 1.15 Billion CNY | 23.38% |
| 2023 Q3 | 815.19 Million CNY | -29.19% |
| 2023 Q2 | 1.15 Billion CNY | 0.0% |
| 2023 FY | 3.93 Billion CNY | -36.15% |
| 2023 Q4 | 822.98 Million CNY | 0.96% |
| 2022 Q3 | 933.07 Million CNY | -24.87% |
| 2022 Q1 | 1.24 Billion CNY | 62.38% |
| 2022 FY | 6.15 Billion CNY | 59.69% |
| 2022 Q4 | 933.07 Million CNY | 0.0% |
| 2022 Q2 | 1.24 Billion CNY | 0.0% |
| 2021 Q2 | 820.14 Million CNY | 0.0% |
| 2021 Q3 | 764.88 Million CNY | -6.74% |
| 2021 Q4 | 764.88 Million CNY | 0.0% |
| 2021 FY | 3.85 Billion CNY | 119.38% |
| 2021 Q1 | 820.14 Million CNY | 42.9% |
| 2020 Q3 | 573.92 Million CNY | 223.82% |
| 2020 Q4 | 573.92 Million CNY | 0.0% |
| 2020 Q2 | 177.23 Million CNY | 0.0% |
| 2020 Q1 | 177.23 Million CNY | -37.47% |
| 2020 FY | 1.75 Billion CNY | 58.41% |
| 2019 Q2 | 190.53 Million CNY | 0.0% |
| 2019 FY | 1.1 Billion CNY | 26.63% |
| 2019 Q4 | 283.45 Million CNY | 0.0% |
| 2019 Q3 | 283.45 Million CNY | 48.77% |
| 2019 Q1 | 190.53 Million CNY | 42.59% |
| 2018 FY | 876.43 Million CNY | 151.38% |
| 2018 Q4 | 133.62 Million CNY | 0.0% |
| 2018 Q3 | 133.62 Million CNY | 4.75% |
| 2018 Q2 | 127.56 Million CNY | 0.0% |
| 2018 Q1 | 127.56 Million CNY | 3.19% |
| 2017 Q4 | 123.62 Million CNY | 0.0% |
| 2017 FY | 348.64 Million CNY | 72.99% |
| 2017 Q2 | 81.72 Million CNY | 0.0% |
| 2017 Q1 | 81.72 Million CNY | 481.35% |
| 2017 Q3 | 123.62 Million CNY | 51.28% |
| 2016 Q2 | 55 Million CNY | 0.0% |
| 2016 Q4 | 14.05 Million CNY | 0.0% |
| 2016 FY | 201.53 Million CNY | 223.87% |
| 2016 Q1 | 55 Million CNY | 41.58% |
| 2015 Q3 | 16.98 Million CNY | 0.0% |
| 2015 Q2 | 16.98 Million CNY | 0.0% |
| 2015 Q1 | 16.98 Million CNY | 0.0% |
| 2015 FY | 62.22 Million CNY | 17.82% |
| 2015 Q4 | 38.85 Million CNY | 128.77% |
| 2014 Q4 | 16.98 Million CNY | 31.73% |
| 2014 Q1 | 12.89 Million CNY | 0.0% |
| 2014 Q3 | 12.89 Million CNY | 0.0% |
| 2014 FY | 52.81 Million CNY | 0.0% |
| 2014 Q2 | 12.89 Million CNY | 0.0% |
| 2013 Q4 | 12.89 Million CNY | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Uni-Bio Science Group Limited | 67.76 Million HKD | -5727.917% |
| CK Life Sciences Int'l., (Holdings) Inc. | 897.95 Million HKD | -339.83% |